A cell culture chamber is for the in vitro production and cultivation of cell layers and organ models with two first and second channels arranged one above the other and separated from one another by a porous membrane with two side surfaces and through which flow can pass, wherein a cell substrate is formed in each case by the side surfaces of the membrane. The cell culture chamber is characterized in that at least the inner walls of the first and the second channels consist of polybutylene terephthalate. Further, a method is for cultivating human or animal cells, and in particular liver sinusoidal endothelial cells, alone and in co-culture with hepatocytes and immune cells.

A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).

Disclosed are methods of preparing CD34+CD43+ hematopoietic progenitor cells (HPC) in vitro according to embodiments of the invention. Also disclosed are methods of differentiating CD34+CD43+ hematopoietic progenitor cells to hematopoietic lineage cells according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e.g., cancer, according to embodiments of the invention.

Described here are a genome-edited primary NK cell, methods that includes editing a genome of a primary natural killer (NK) cell, and methods of administering a genome-edited primary NK cell. The primary NK cell may be rested or stimulated.

Methods of producing stem cell conditioned media to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury.

The present invention relates to a method of preparing cancer antigen-specific CD8+ T cells comprising (a) activating the CD8+ T cells from among PBMCs comprising cancer antigen-specific CD8+ T cells, and then expressing a co-stimulatory factor of these CD8+ T cells; (b) selecting the CD8+ T cells expressing a co-stimulatory factor among the cells activated in step (a); (c) increasing the number of CD8+ T cells selected in step (b); (d) freezing the CD8+ T cells obtained in step (c); and (e) thawing the CD8+ T cells that were frozen in step (d).

Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates.

Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD8.sup.+CD39.sup.+CD103.sup.+ T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD8.sup.+CD39.sup.+CD103.sup.+ T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD8.sup.+CD39.sup.+CD103.sup.+ T cells. In addition, methods are disclosed for expanding CD8.sup.+CD39.sup.+CD103.sup.+ T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD8.sup.+CD39.sup.+CD103.sup.+ T cells in a biological sample from a subject.

Disclosed herein are bioreactor systems and methods of utilizing said systems.

According to various embodiments, there is provided a bioreactor module including a container; a holder removably receivable in the container, the holder adapted to hold a scaffold containing an inherent vascular network; an inlet connectable to a vessel of the inherent vascular network of the scaffold; an inflatable device disposed substantially near a base of the container, the inflatable device having a conduit extending through a wall of the container; and a pair of electrodes attached to opposing walls of the container.